Estimation of VLDL, IDL, LDL, HDL2, apoA-I, and apoB from the Friedewald inputs—apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes
暂无分享,去创建一个
K. Kaski | M. Taskinen | J. Heikkonen | C. Forsblom | P. Groop | M. Savolainen | M. Ala-Korpela | L. Tenkanen | M. Jauhiainen | P. Kovanen | V. Mäkinen | Y. Kesäniemi | M. Hannuksela | Y. Hiltunen | J. Niemi | Y. Kesäniemi | Markku J. Savolainen | Petri T. Kovanen
[1] Nicholas J Wareham,et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. , 2009, Journal of the American College of Cardiology.
[2] Steven Hawken,et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study , 2008, The Lancet.
[3] K. Kaski,et al. Metabolic Phenotypes, Vascular Complications, and Premature Deaths in a Population of 4,197 Patients With Type 1 Diabetes , 2008, Diabetes.
[4] Michael Miller,et al. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment , 2008, Current opinion in endocrinology, diabetes, and obesity.
[5] K. Kaski,et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death , 2008, Molecular systems biology.
[6] S. Chun,et al. Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula , 2008, Clinical chemistry and laboratory medicine.
[7] A. Pradhan,et al. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. , 2007, Nutrition reviews.
[8] M. Taskinen,et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes , 2007, Diabetologia.
[9] B. Hansel,et al. HDL‐c is a powerful lipid predictor of cardiovascular diseases , 2007, International journal of clinical practice.
[10] James O. Mudd,et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. , 2007, Journal of the American College of Cardiology.
[11] T. Orchard,et al. The Prediction of Major Outcomes of Type 1 Diabetes: a 12-Year Prospective Evaluation of Three Separate Definitions of the Metabolic Syndrome and Their Components and Estimated Glucose Disposal Rate , 2007, Diabetes Care.
[12] M. Elisaf,et al. LDL cholesterol estimation in patients with the metabolic syndrome , 2006, Lipids in Health and Disease.
[13] R. Krauss,et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel , 2006, Journal of internal medicine.
[14] I. Ockene,et al. Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with serum triglyceride levels < or =4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[15] Nader Rifai,et al. Non–High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men , 2005, Circulation.
[16] P. Libby,et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. , 2005, Circulation.
[17] I. Young,et al. A rapid methodology for the isolation of intermediate-density lipoprotein: characterization of lipid composition and apoprotein content. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[18] G. Dagenais,et al. Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[19] D. Capuzzi,et al. High-density lipoprotein subfractions and risk of coronary artery disease , 2004, Current atherosclerosis reports.
[20] J. Fruchart,et al. Atherogenic Lipoprotein Particles in Atherosclerosis , 2004, Circulation.
[21] M. Savolainen,et al. Screening for a prevalent LDL receptor mutation in patients with severe hypercholesterolaemia , 1991, Human Genetics.
[22] M. Jauhiainen,et al. PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma Published, JLR Papers in Press, June 16, 2003. DOI 10.1194/jlr.M300059-JLR200 , 2003, Journal of Lipid Research.
[23] A. Wägner,et al. The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patients. , 2003, Clinical biochemistry.
[24] Yrjö Hiltunen,et al. Application of Quantitative Artificial Neural Network Analysis to 2D NMR Spectra of Hydrocarbon Mixtures , 2002, J. Chem. Inf. Comput. Sci..
[25] H. Ginsberg. New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism , 2002, Circulation.
[26] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .
[27] N. Rifai,et al. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. , 2002, Clinical chemistry.
[28] I. Holme,et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.
[29] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[30] T. Shoji,et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.
[31] T. Shoji,et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. , 1997, Atherosclerosis.
[32] J. Ordóñez‐Llanos,et al. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. , 1997, Clinical chemistry.
[33] R. Krauss,et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. , 1997, Circulation.
[34] W. Baxt. Application of artificial neural networks to clinical medicine , 1995, The Lancet.
[35] M Ala-Korpela,et al. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. , 1994, Journal of lipid research.
[36] K. Huttunen,et al. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. , 1994, Kidney international.
[37] D. Waters,et al. Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events , 1993, Circulation.
[38] Heekuck Oh,et al. Neural Networks for Pattern Recognition , 1993, Adv. Comput..
[39] Y. Marcel,et al. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. , 1992, Journal of lipid research.
[40] M. Savolainen,et al. Magnitude of dietary effects on plasma cholesterol concentration: role of sex and apolipoprotein E phenotype. , 1991, Atherosclerosis.
[41] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[42] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[43] A. Beckett,et al. AKUFO AND IBARAPA. , 1965, Lancet.
[44] D.,et al. Regression Models and Life-Tables , 2022 .